EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Environmental risk and market approval for human pharmaceuticals

Davide Fumagalli

Monash Bioethics Review · 2024-12 · 42 (S1) · 105-124

DOI: 10.1007/s40592-024-00195-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Monash Bioethics Review, online erschienen am 03.07.2024. Verfasst von Davide Fumagalli. Beteiligte Einrichtung: Department Philosophy, Linguistics and Theory of Science, University of Gothenburg, Renstromsgatan 6, 412 55, Gothenburg, Sweden. davide.fumagalli@gu…. Hauptthemen laut MEDLINE: Drug Approval, Drug Industry, Environmental Pollution. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet, University of Gothenburg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This paper contributes to the growing discussion about how to mitigate pharmaceutical pollution, which is a threat to human, animal, and environmental health as well as a potential driver of antimicrobial resistance. It identifies market approval of pharmaceuticals as one of the most powerful ways to shape producer behavior and highlights that applying this tool raises ethical issues given that it might impact patients’ access to medicines. The paper identifies seven different policy options that progressively give environmental considerations increased priority in the approval process, identifies ethically relevant interests affected by such policies, and makes explicit tensions and necessary tradeoffs between these interests. While arguing that the current European regulation gives insufficient weight to environmental considerations, the paper highlights concerns with the strongest policy options, on the grounds that these may very well endanger patients’ access to effective medication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalDrug IndustryEnvironmental PollutionHumansEuropePharmaceutical Preparations

Stichwörter der Autor:innen

AntibioticsAntimicrobial resistanceEnvironmental policyEthicsPharmaceutical pollution

Substanzen

Pharmaceutical Preparations

Autor:innen und Institutionen

  • Department Philosophy, Linguistics and Theory of Science, University of Gothenburg, Renstromsgatan 6, 412 55, Gothenburg, Sweden. davide.fumagalli@gu.se.

Förderung

  • Vetenskapsrådet
  • University of Gothenburg

Zitieren

APA

Fumagalli, D. (2024). Environmental risk and market approval for human pharmaceuticals. Monash Bioethics Review, 42(S1), 105-124. https://doi.org/10.1007/s40592-024-00195-1

Vancouver

Fumagalli D. Environmental risk and market approval for human pharmaceuticals. Monash Bioethics Review. 2024;42(S1):105-124. doi:10.1007/s40592-024-00195-1

BibTeX
@article{Fumagalli2024,
  author = {Fumagalli, Davide},
  title = {Environmental risk and market approval for human pharmaceuticals},
  journal = {Monash Bioethics Review},
  year = {2024},
  volume = {42},
  number = {S1},
  pages = {105--124},
  doi = {10.1007/s40592-024-00195-1}
}
Kostenlos starten →